Autolus Limited
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Autolus Limited sits in the upper quartile of US sponsors by registered trial count (#2,411 of 15,742 sponsors by registered trial count).
Autolus Limited: 5 sponsored US clinical trials, 3 recruiting.
Autolus Limited sponsors 5 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia, with 2 trials.
Upper-quartile sponsor footprint
Autolus Limited sits in the upper quartile of the sponsor corpus (#2,411 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
5 total, page 1 of 1
Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)
NCT07053800
Obe-cel in Refractory Progressive Forms of Multiple Sclerosis
NCT07139743
A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
NCT06173518
A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)
NCT04404660
Cluster of Differentiation Antigen 19/22(CD19/22) CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma
NCT03287817
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 1 |
What is open in the Autolus Limited pipeline
3 recruiting of 5 indexed (60% open).
Phase mix: 0 late (III/IV) vs 5 early (I/II) (early-phase heavy).
Top condition: Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (2 trials), 2 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Autolus Limited: open-pipeline peers nationwide
Peers matched on 5 registered trials and 60% open enrollment, not the therapeutic-area sidebar.
Autolus Limited sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 5 trials (± recruiting share)
- 4YouandMe · 5 trials · 0% recruiting
- Abbott Rapid Dx · 5 trials · 0% recruiting
- Access Business Group · 5 trials · 0% recruiting
- Acera Surgical · 5 trials · 20% recruiting
Sponsors near 60% open enrollment (± trial volume)
- Alaska Native Tribal Health Consortium · 60% recruiting · 5 trials
- Anwaar Saeed · 60% recruiting · 5 trials
- Beam Therapeutics · 60% recruiting · 5 trials
- Bio-Path Holdings · 60% recruiting · 5 trials
Related
What to do with this Autolus Limited page
5 registered trials is a research-attention snapshot, not an endorsement of Autolus Limited or any single study.
- 3 of Autolus Limited's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia is the condition Autolus Limited studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Autolus Limited pipeline card: 5 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.